Silver Book Fact

Cost-effectiveness of flu vaccine

Vaccination for pandemic influenza (pH1N1) prior to an outbreak produces incremental cost-effectiveness ratios for individuals without high risk conditions, ranging from $8,000 to $52,000 per quality-adjusted life year.

Prosser, Lisa A., Tara A. Lavelle, Anthony E. Fiore, Carolyn B. Bridges, Carrie Reed, et al. Cost-Effectiveness of 2009 Pandemic Influenza A (H1N1) Vaccination in the United States. PLoS ONE. 2011; 6(7). http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0022308

Reference

Title
Cost-Effectiveness of 2009 Pandemic Influenza A (H1N1) Vaccination in the United States
Publication
PLoS ONE
Publication Date
2011
Authors
Prosser, Lisa A., Tara A. Lavelle, Anthony E. Fiore, Carolyn B. Bridges, Carrie Reed, et al.
Volume & Issue
Volume 6, Issue 7
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Vaccines in development 2013
    Biopharmaceutical research companies are developing 271 vaccines for infectious diseases, cancer, neurological disorders, allergies, and other diseases.  
  • Flu vaccine use can reduce illness risk in U.S. by 60%
    Recent studies from the Centers for Disease Control and Prevention show that the influenza vaccine can reduce the risk of illness in the overall U.S. population by around 60%. …  
  • Vaccines in development 2013
    137 vaccines are currently in development in the U.S. for infectious diseases.  
  • Diptheria vaccine significantly reduced annual cases
    Vaccination has played a significant role in reducing diphtheria cases from 80,000 in 1975 to less than 10,000 per year.  
  • Shingles vaccine could improve QALY and save money
    Vaccination of 1 million people age 60 and over with the shingles vaccine would result in 11,919 non-discounted and 8,782 discounted QALYs (quality of life years) gained and save around…